Stay updated on Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma

Sign up to get notified when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page

  1. Check
    3 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error, and its footer revision identifier was updated from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T21:43:43.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T04:14:45.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error instead of the trial details, making the study information inaccessible and disrupting navigation to related study data.
    Difference
    19%
    Check dated 2026-09-21T22:30:04.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    The page now shows a new revision tag for v3.6.6, replacing the previous v3.6.5. This indicates a software or UI update rather than a substantive change to the study details.
    Difference
    0.1%
    Check dated 2026-08-31T18:29:00.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    The page now shows a new revision identifier (v3.6.5), replacing the previous v3.6.4, indicating a deployment of a newer site version and no evident changes to the study content.
    Difference
    0.1%
    Check dated 2026-08-10T12:59:23.000Z thumbnail image
  7. Check
    87 days ago
    Change Detected
    Summary
    Revision: v3.6.4 was added and Revision: v3.6.3 was removed. This reflects a site-wide update to the ClinicalTrials.gov interface.
    Difference
    0.1%
    Check dated 2026-07-27T05:56:46.000Z thumbnail image

Stay in the know with updates to Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma

Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.